Treatment of Mild Psoriatic Arthritis with Oligoarticular or Entheseal Disease

This protocol covers the first-line management of mild psoriatic arthritis in patients presenting with oligoarticular disease (few swollen joints) or entheseal involvement, without poor prognostic factors and with limited skin involvement — in whom biologic DMARDs and JAK inhibitors are not appropriate.

Clinical Scenario

Mild disease is defined as oligoarticular or entheseal disease without poor prognostic factors and limited skin involvement. When both biologic DMARDs (bDMARDs) and JAK inhibitors are not appropriate for the patient, this specific management pathway applies. The pattern of joint involvement — characterised by swollen joints in a limited distribution — shapes the therapeutic approach.

Treatment Approach

Management in this setting centres on symptomatic control of musculoskeletal manifestations. Anti-inflammatory therapy is used to relieve musculoskeletal signs and symptoms, and a targeted local intervention may be considered as adjunctive support. The complete structured regimen — including therapeutic sequencing, monitoring parameters, and escalation criteria — is available in the full protocol.

Treatment target: Relief of musculoskeletal signs and symptoms within 4 weeks

Symptomatic treatment in this context is intended to be short term.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2024-225531

'Mild disease' is defined as oligoarticular or entheseal disease without poor prognostic factors and limited skin involvement.

Non-steroidal anti-inflammatory drugs may be used to relieve musculoskeletal signs and symptoms; local injections of glucocorticoids may be considered as adjunctive therapy.

The use of symptomatic treatments alone should usually be short term, for example, limited to 4 weeks or so.

View source ↗